Clinical Trial Update: Phase ⅡStudy of Tyroserleutide for Injection in Hepatocellular Carcinoma(HCC) Patients

View source ↗

Summary

Phase II clinical trial update evaluating Tyroserleutide for injection in hepatocellular carcinoma; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Tyroserleutide

Snippet

Sponsor: Shenzhen Kangzhe Pharmaceutical Co., Ltd. | Conditions: Hepatocellular Carcinoma | Status: UNKNOWN